Provides access to Serina POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina...
WIXOM, Mich., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment...
AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced that its Founder and...
Company’s Common Stock Listed Under Symbol “AGE” AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics...
ST. LOUIS, Sept. 28 /PRNewswire-FirstCall/ -- A.G. Edwards, Inc., (NYSE:AGE) announced today that the company's stockholders have approved the Agreement and Plan of Merger among Wachovia...
Improved savings rate contributed to increase; home equity rate weighs down score. ST. LOUIS, Sept. 25 /PRNewswire-FirstCall/ -- At 649, the September 2007 Nest Egg Score -- released today by...
ST. LOUIS, Sept. 20 /PRNewswire-FirstCall/ -- A.G. Edwards, Inc. (NYSE:AGE) today announced results for the second quarter and first half of fiscal 2008, which ended August 31, 2007. Net...
Los Alamos, N.M., Tops List for Second Straight Year ST. LOUIS, Sept. 12 /PRNewswire-FirstCall/ -- A.G. Edwards (NYSE:AGE) today released its third annual "Nest Egg Index," which ranks America's...
ST. LOUIS, Aug. 29 /PRNewswire-FirstCall/ -- A special meeting of stockholders of A.G. Edwards, Inc., a Delaware corporation, is being held on Friday, Sept. 28, 2007, at 10:00 a.m., local time...
ST. LOUIS, Aug. 23 /PRNewswire-FirstCall/ -- The Board of Directors of A.G. Edwards, Inc. (NYSE:AGE) declared a regular quarterly cash dividend of 20 cents per share, payable on October 1, 2007...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約